Phase 4 Trial of Abaloparatide Before Knee Arthroplasty Marked Completed

A clinical trial studying abaloparatide administered before total knee arthroplasty was updated to completed status on June 5, 2026. The study, registered as NCT04167163 and titled "Abaloparatide Before Total Knee Arthroplasty," is a Phase 4 trial. Phase 4 trials are conducted after a drug has received approval to gather additional data in real world or specific clinical settings. The status update indicates the trial has finished its planned activities, according to the record on ClinicalTrials.gov. No results or outcome data were included in this update. The registration reflects only the change in trial status and does not describe findings related to safety or effectiveness. Abaloparatide is an approved compound, and this trial represents one of the studies examining its use in a surgical context involving total knee arthroplasty. Further details about the trial design, enrollment, or eventual results would need to be found in subsequent postings to the registry. Readers interested in the compound can consult the linked overview for additional context on abaloparatide's approved uses and background.